PubMed

Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics.

Prosser LA, Stinnett AA, Goldman PA, Williams LW, Hunink MG, Goldman L, Weinstein MC.

Ann Intern Med. 2000 May 16;132(10):769-79.PMID: 10819699 [PubMed - indexed for MEDLINE]Related articlesFree article

Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.

Pletcher MJ, Lazar L, Bibbins-Domingo K, Moran A, Rodondi N, Coxson P, Lightwood J, Williams L, Goldman L.

Ann Intern Med. 2009 Feb 17;150(4):243-54.PMID: 19221376 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.PMID: 16780391 [PubMed - indexed for MEDLINE]Related articles

Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia.

Blake GJ, Ridker PM, Kuntz KM.

Am J Med. 2003 Apr 15;114(6):485-94.PMID: 12727581 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness of pravastatin for primary prevention of coronary artery disease in Japan.

Nagata-Kobayashi S, Shimbo T, Matsui K, Fukui T.

Int J Cardiol. 2005 Sep 30;104(2):213-23.PMID: 16168816 [PubMed - indexed for MEDLINE]Related articles

A systematic review and economic evaluation of statins for the prevention of coronary events.

Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N.

Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. Review.PMID: 17408535 [PubMed - indexed for MEDLINE]Related articlesFree article

Ezetimibe for the treatment of hypercholesterolaemia: a systematic review and economic evaluation.

Ara R, Tumur I, Pandor A, Duenas A, Williams R, Wilkinson A, Paisley S, Chilcott J.

Health Technol Assess. 2008 May;12(21):iii, xi-xiii, 1-212. Review.PMID: 18485273 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction.

Ganz DA, Kuntz KM, Jacobson GA, Avorn J.

Ann Intern Med. 2000 May 16;132(10):780-7. Erratum in: Ann Intern Med 2002 Apr 16;136(8):635. PMID: 10819700 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of statin therapy for the primary prevention of major coronary events in individuals with type 2 diabetes.

Brandle M, Davidson MB, Schriger DL, Lorber B, Herman WH.

Diabetes Care. 2003 Jun;26(6):1796-801.PMID: 12766112 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.

Hay JW, Sterling KL.

Pharmacoeconomics. 2005;23(2):133-41.PMID: 15748088 [PubMed - indexed for MEDLINE]Related articles

Lipid-lowering for prevention of coronary heart disease: what policy now?

Ul Haq I, Ramsay LE, Pickin DM, Yeo WW, Jackson PR, Payne JN.

Clin Sci (Lond). 1996 Oct;91(4):399-413. Erratum in: Clin Sci (Colch) 1996 Dec;91(6):773-4. PMID: 8983865 [PubMed - indexed for MEDLINE]Related articles

Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.

Cobos A, Jovell AJ, García-Altés A, García-Closas R, Serra-Majem L.

Clin Ther. 1999 Nov;21(11):1924-36.PMID: 10890264 [PubMed - indexed for MEDLINE]Related articles

Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.

Ara R, Pandor A, Tumur I, Paisley S, Duenas A, Williams R, Wilkinson A, Durrington P, Chilcott J.

Clin Ther. 2008 Aug;30(8):1508-23.PMID: 18803993 [PubMed - indexed for MEDLINE]Related articles

Cost-effectiveness analysis of rosuvastatin versus atorvastatin, simvastatin, and pravastatin from a Canadian health system perspective.

Costa-Scharplatz M, Ramanathan K, Frial T, Beamer B, Gandhi S.

Clin Ther. 2008 Jul;30(7):1345-57.PMID: 18691996 [PubMed - indexed for MEDLINE]Related articles

A pharmacoeconomic evaluation of statins in the treatment of hypercholesterolaemia in the primary care setting in Spain.

Tárraga-López PJ, Celada-Rodríguez A, Cerdán-Oliver M, Solera-Albero J, Ocaña-López JM, López-Cara MA, De Miguel-Clave J.

Pharmacoeconomics. 2005;23(3):275-87. Erratum in: Pharmacoeconomics. 2006;24(1):106. PMID: 15836008 [PubMed - indexed for MEDLINE]Related articles

The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease. Estimating the benefits of increasing HDL-C.

Hamilton VH, Racicot FE, Zowall H, Coupal L, Grover SA.

JAMA. 1995 Apr 5;273(13):1032-8.PMID: 7897787 [PubMed - indexed for MEDLINE]Related articles

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Pignone M, Earnshaw S, Tice JA, Pletcher MJ.

Ann Intern Med. 2006 Mar 7;144(5):326-36.PMID: 16520473 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of prescribing statins according to pharmaceutical benefits scheme criteria.

Lim SS, Vos T, Peeters A, Liew D, McNeil JJ.

Med J Aust. 2001 Nov 5;175(9):459-64.PMID: 11758073 [PubMed - indexed for MEDLINE]Related articles

A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.

Wilson K, Marriott J, Fuller S, Lacey L, Gillen D.

Pharmacoeconomics. 2003;21 Suppl 1:1-11.PMID: 12648030 [PubMed - indexed for MEDLINE]Related articles

Pravastatin. A pharmacoeconomic review of its use in primary and secondary prevention of coronary heart disease.

Coukell AJ, Wilde MI.

Pharmacoeconomics. 1998 Aug;14(2):217-36. Review.PMID: 10186462 [PubMed - indexed for MEDLINE]Related articles